Abstract
Major advances have been made in the early detection of CMV infection after marrow transplant by the introduction of the polymerase chain reaction (PCR) and the CMV antigenemia assay. Numerous studies have established clinical correlations of these techniques but there is a need for technical standardization as assay sensitivity may vary considerably with different modifications. Current prevention strategies for CMV disease after marrow transplantation, including options on how the antigenemia assay and PCR assays may be used in early treatment strategies, are discussed.
Publication types
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, P.H.S.
-
Review
MeSH terms
-
Acyclovir / therapeutic use
-
Antibodies, Viral / blood
-
Antigens, Viral / blood
-
Bone Marrow Transplantation / adverse effects*
-
Cytomegalovirus / genetics
-
Cytomegalovirus / growth & development
-
Cytomegalovirus / immunology
-
Cytomegalovirus / isolation & purification
-
Cytomegalovirus Infections* / diagnosis
-
Cytomegalovirus Infections* / drug therapy
-
Cytomegalovirus Infections* / mortality
-
Cytomegalovirus Infections* / prevention & control
-
Double-Blind Method
-
Ganciclovir / administration & dosage
-
Ganciclovir / adverse effects
-
Ganciclovir / therapeutic use
-
Humans
-
Leukocytes / virology
-
Polymerase Chain Reaction
-
Predictive Value of Tests
-
Premedication
-
Prospective Studies
-
Randomized Controlled Trials as Topic
-
Survival Analysis
-
Virus Activation
-
Virus Cultivation
Substances
-
Antibodies, Viral
-
Antigens, Viral
-
Ganciclovir
-
Acyclovir